|
28 Apr 2008 |
Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics
|
|
28 Apr 2008 |
Targeted Genetics Announces Data From First Gene Therapy Trial for Leber's Congenital Amaurosis in New England Journal of Medicine
|
|
25 Apr 2008 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
|
|
24 Apr 2008 |
ReNeuron announces further pre-clinical data with its ReN003 programme for diseases of the retina
|
|
23 Apr 2008 |
Lorus initiates development program exploring novel route of administration for LOR-2040
|
|
21 Apr 2008 |
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
|
|
18 Apr 2008 |
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
|
|
17 Apr 2008 |
GlaxoSmithKline and Regulus Therapeutics form strategic alliance to develop microRNA targeted therapeutics to treat inflammatory diseases
|
|
16 Apr 2008 |
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
|
|
16 Apr 2008 |
Aldagen Announces Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants in Pediatric Patients With Inherited Metabolic Diseases
|
|
14 Apr 2008 |
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
|
|
09 Apr 2008 |
Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
|
|
08 Apr 2008 |
Bristol-Myers Squibb Selects Isis Drug Targeting PCSK9 as Development Candidate for Prevention and Treatment of Cardiovascular Disease
|
|
07 Apr 2008 |
Danish biotech company's restorative Alzheimer's product has successfully been implanted in patients
|
|
07 Apr 2008 |
Targeted Genetics Acquires Rights to siRNA Development Program in Huntington's Disease From Sirna Therapeutics
|
|
01 Apr 2008 |
Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
|
|
01 Apr 2008 |
Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction
|
|
31 Mar 2008 |
Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium
|
|
31 Mar 2008 |
Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis Platform in HIV at Keystone Symposia
|
|
28 Mar 2008 |
Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
|
|
20 Mar 2008 |
Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic
|
|
19 Mar 2008 |
Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
|
|
18 Mar 2008 |
Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
|
|
17 Mar 2008 |
Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
|
|
14 Mar 2008 |
Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
|
